Aura Biosciences AURA 深 滬
已收盤 11-06 16:00:00 美东时间
6.56
+0.220
+3.47%
華盛通- 最 高6.66
- 今 開6.35
- 成交量 85.90万股
- 最 低 6.17
- 昨 收 6.34
- 總市值 6.80亿
- 52周最高 9.535
- 市盈率 靜 --
- 換手率 0.83%
- 52周最低 4.73
- 委 比 10.68%
- 總股本 1.04亿
- 歷史最高 26.16
- 量 比 1.16
- 振 幅 7.73%
- 歷史最低 4.345
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aura Biosciences收涨3.47%，成交额563.44万美元
11月7日，Aura Biosciences（AURA）收涨3.47%，报6.56美元，成交额563.44万美元，市值6.8亿美元。 行情数据 • 开盘价：6...
11-07 06:53
Aura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences announced that CEO Natalie Holles will participate in the Stifel 2026 Healthcare Conference on November 10, 2026, with a fireside chat at 2:40 p.m. ET. The live webcast will be available on the company’s website, with a replay archived for 90 days. Aura is developing bel-sar, a first-in-class therapy for ocular cancers, targeting vision preservation and tumor growth arrest. The Phase 3 study for early choroidal melanoma is fully...
11-03 21:02
Aura Biosciences收跌2.46%，成交额327.57万美元
10月31日，Aura Biosciences（AURA）收跌2.46%，报6.14美元，成交额327.57万美元，市值6.37亿美元。 行情数据 • 开盘价...
10-31 05:58
Diagonal Therapeutics Appoints Industry Veteran Jeremy Bender, Ph.D., M.B.A., as Chair of the Board of Directors
Diagonal Therapeutics appoints Jeremy Bender, Ph.D., M.B.A., as Board Chair, bringing over 20 years of biotech leadership and drug development experience. The company is advancing DIAG723, a multispecific clustering antibody targeting hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH), currently in a Phase 1/2 clinical trial. Bender's expertise will support the company's pipeline progress and strategic growth.
10-29 12:00
Aura Biosciences收跌1.9%，成交额563.98万美元
10月27日，Aura Biosciences（AURA）收跌1.9%，报6.18美元，成交额563.98万美元，市值6.41亿美元。 行情数据 • 开盘价：...
10-27 05:59
Aura Biosciences收跌3.79%，成交额470.22万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:01
Aura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences, Inc. announced that its CEO, Natalie Holles, will participate in Morgan Stanley's 24th Annual Global Healthcare Conference on September 16, 2026. The company is developing bel-sar, a first-in-class therapy for ocular cancers, which combines tumor necrosis and immune activation. The Phase 3 study for early choroidal melanoma is fully enrolled, with additional studies ongoing. Aura aims to improve outcomes for patients with ocular...
09-02 20:01
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
LeonaBio reported progress on its Phase 3 ELAINE-3 trial for lasofoxifene in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, with enrollment on track to complete by Q4 2026 and topline data expected in H2 2027. The company highlighted lasofoxifene's potential as a transformative treatment and discussed its favorable safety and efficacy profile from earlier studies. Financially, LeonaBio ended Q2 2026 with $51.1 million in cash ...
08-14 20:05
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Aura Biosciences (NASDAQ:AURA) with a Buy and lowers the price target from $24 to $18.
08-12 00:11
